Drugs / MAA868
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04213807 | Dec 2019 → Dec 2020 | atrial fibrillation | Anthos Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03398434 | Oct 2018 → Nov 2019 | atrial fibrillation | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03393481 | Oct 2018 → Jan 2020 | thrombotic disease | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAA868 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03398434 ↗ |
| Route | Subcutaneous | “single administration, subcutaneous” NCT03393481 ↗ |